ENLV
EnlivexBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Allocetra progresses from first U.S. dosing toward broader enrollment and later data, while the Rain treasury update and financing actions support additional valuation optionality for event-driven buyers.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Allocetra is still in Phase 2b; efficacy data are not yet available and execution on enrollment remains key. [#PR-2026-05-18]
Momentum
87
Value
41
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.10 · Bear $0.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.00
Why
Momentum87 · Δ7d -
Value41 · Δ7d +0.1
Sentiment40 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
40
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 87.4 / Value 41.1 / Sentiment 39.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$208.12M
Beta
1.61
Shares Out
237.38M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.72
Rev YoY
-
EPS YoY
+25.0%
Gross Margin
-
Op Margin
-
Net Debt
-$23.5M
Current Ratio
6.43
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology